Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Foghorn Therapeutics Inc. (FHTX)
USD5.35
-0.03 (-0.49%)
US NASDAQ Healthcare Biotechnology
Address
500 Technology Square 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Adrian H. Gottschalk
Website
foghorntx.com
IPO
2020-10-23
CIK 1822462 ISIN US3441741077
Description
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.35
-0.03 (-0.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
174.5K
Beta
2.89
Float Shares
27.41M
Free Float %
46.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.23% | +0.00% | -9.89% | -24.65% | -9.89% | -20.74% | +4.90% | -33.33% | -61.61% | -76.38% | -76.38% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
5.35
Low
11.00
+105.5%
Consensus
11.67
+118.0%
Median
12.00
+124.1%
High
12.00
+124.1%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
11.67
+118.0%
|
| All Time | 9 |
14.00
+161.5%
|
Quality scores
Altman Z-Score
-3.93
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+36.8% ★ Q1'26: -45.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+25.3% Q1'26: +3.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-359.0% Q1'26: -773.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-265.6% Q1'26: -660.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +39.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.7% Q1'26: +10.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.52× Q1'26: -0.49× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
430.0K
est: 686.0K (-37.3%)
|
1.32M
est: 1.32M (+0.3%)
|
19.23M
est: 22.92M (-16.1%)
|
34.16M
est: 35.19M (-2.9%)
|
22.60M
est: 29.53M (-23.5%)
|
30.91M
est: 31.83M (-2.9%)
|
25.84M
12.00M – 35.36M
-18.8% YoY
|
37.42M
19.87M – 60.52M
+44.8% YoY
|
53.26M
51.59M – 54.94M
+42.3% YoY
|
66.88M
29.44M – 108.01M
+25.6% YoY
|
150.09M
66.07M – 242.38M
+124.4% YoY
|
| EBITDA |
-67.20M
est: -686.0K (-9,696.5%)
|
-96.19M
est: -1.32M (-7,213.5%)
|
-113.82M
est: -22.92M (-396.6%)
|
-104.46M
est: -35.19M (-196.9%)
|
-97.17M
est: -29.53M (-229.0%)
|
-78.78M
est: -31.83M (-147.5%)
|
-25.84M
-35.36M – -12.00M
+18.8% YoY
|
-37.42M
-60.52M – -19.87M
-44.8% YoY
|
-53.26M
-54.94M – -51.59M
-42.3% YoY
|
-66.88M
-108.01M – -29.44M
-25.6% YoY
|
-150.09M
-242.38M – -66.07M
-124.4% YoY
|
| EBIT |
-68.53M
est: -686.0K (-9,889.9%)
|
-99.41M
est: -1.32M (-7,458.9%)
|
-117.14M
est: -22.92M (-411.1%)
|
-107.91M
est: -35.19M (-206.7%)
|
-100.29M
est: -29.53M (-239.5%)
|
-82.11M
est: -31.83M (-157.9%)
|
-25.84M
-35.36M – -12.00M
+18.8% YoY
|
-37.42M
-60.52M – -19.87M
-44.8% YoY
|
-53.26M
-54.94M – -51.59M
-42.3% YoY
|
-66.88M
-108.01M – -29.44M
-25.6% YoY
|
-150.09M
-242.38M – -66.07M
-124.4% YoY
|
| Net Income |
-68.80M
est: -230.30M (+70.1%)
|
-101.32M
est: -142.96M (+29.1%)
|
-108.88M
est: -131.06M (+16.9%)
|
-98.43M
est: -86.45M (-13.9%)
|
-86.62M
est: -97.17M (+10.9%)
|
-74.28M
est: -69.41M (-7.0%)
|
-71.96M
-81.20M – -51.08M
-3.7% YoY
|
-54.08M
-62.71M – -45.44M
+24.9% YoY
|
-56.89M
-77.51M – 21.65M
-5.2% YoY
|
-38.00M
-68.37M – -10.35M
+33.2% YoY
|
18.26M
4.97M – 32.86M
+148.1% YoY
|
| SGA |
11.25M
est: 6.37M (+76.5%)
|
21.73M
est: 12.21M (+77.9%)
|
30.75M
est: 212.83M (-85.6%)
|
32.37M
est: 148.95M (-78.3%)
|
28.36M
est: 125.03M (-77.3%)
|
27.55M
est: 134.75M (-79.6%)
|
109.40M
50.80M – 149.68M
-18.8% YoY
|
158.42M
84.13M – 256.20M
+44.8% YoY
|
225.48M
218.38M – 232.58M
+42.3% YoY
|
283.12M
124.63M – 457.21M
+25.6% YoY
|
635.35M
279.67M – 1.03B
+124.4% YoY
|
| EPS |
-1.90
est: -4.20 (+54.7%)
|
-2.78
est: -2.60 (-6.8%)
|
-2.62
est: -2.39 (-9.7%)
|
-2.34
est: -1.94 (-20.6%)
|
-1.58
est: -1.54 (-2.4%)
|
-1.18
est: -1.11 (-6.6%)
|
-1.02
-1.29 – -0.81
+7.9% YoY
|
-0.88
-1.00 – -0.72
+13.2% YoY
|
-0.65
-1.23 – 0.34
+26.6% YoY
|
-0.60
-1.09 – -0.16
+7.0% YoY
|
0.29
0.08 – 0.52
+148.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-75.24M
OE per share TTM
-1.15
Owner's Yield
-25.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
258.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
104
Total invested
212.43M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Noubar Afeyan | 12.67M | 35.50% | — | 12.67M | — | 12.67M | IN | — | 2020-10-29 | ↗ |
| 2 | Flagship Ventures Fund V General Partner LLC | 9.33M | 26.10% | — | 9.33M | — | 9.33M | OO | — | 2020-10-29 | ↗ |
| 3 | Flagship Ventures Fund V, L.P. | 9.33M | 26.10% | — | 9.33M | — | 9.33M | PN | — | 2020-10-29 | ↗ |
| 4 | BVF Inc. | 5.55M | 9.99% | — | — | — | 5.55M | CO | Delaware | 2024-05-30 | ↗ |
| 5 | BVF Partners L.P. | 5.55M | 9.99% | — | — | — | 5.55M | IA, PN | Delaware | 2024-05-30 | ↗ |
| 6 | Mark N. Lampert | 5.55M | 9.99% | — | — | — | 5.55M | IN | Delaware | 2024-05-30 | ↗ |
| 7 | BVF GP Holdings LLC | 5.24M | 9.40% | — | — | — | 5.24M | OO | Delaware | 2024-05-30 | ↗ |
| 8 | OR | 4.00M | 9.70% | 4.00M | — | 4.00M | — | CO | Indiana | 2021-12-13 | ↗ |
| 9 | Ph.D. | 3.96M | 11.05% | 3.96M | — | 3.96M | — | IN | Massachusetts | 2021-04-19 | ↗ |
| 10 | BVF I GP LLC | 3.05M | 5.50% | — | — | — | 3.05M | OO | Delaware | 2024-05-30 | ↗ |
| 11 | Biotechnology Value Fund, L.P. | 3.05M | 5.50% | — | — | — | 3.05M | PN | Delaware | 2024-05-30 | ↗ |
| 12 | Deerfield Management Company, L.P. | 2.94M | 5.31% | — | 2.94M | — | — | PN | Delaware | 2024-09-20 | ↗ |
| 13 | Deerfield Mgmt, L.P. | 2.94M | 5.31% | — | 2.94M | — | — | PN | Delaware | 2024-09-20 | ↗ |
| 14 | Deerfield Partners, L.P. | 2.94M | 5.31% | — | 2.94M | — | — | PN | Delaware | 2024-09-20 | ↗ |
| 15 | James E. Flynn | 2.94M | 5.31% | — | 2.94M | — | — | IN | Delaware | 2024-09-20 | ↗ |
| 16 | BVF II GP LLC | 2.19M | 4.00% | — | — | — | 2.19M | OO | Delaware | 2024-05-30 | ↗ |
| 17 | Biotechnology Value Fund II, L.P. | 2.19M | 4.00% | — | — | — | 2.19M | PN | Delaware | 2024-05-30 | ↗ |
| 18 | Seth A. Klarman | 2.14M | 5.97% | — | 2.14M | — | — | HC, IN | Massachusetts | 2021-02-04 | ↗ |
| 19 | The Klarman Family Foundation | 2.14M | 5.97% | — | 2.14M | — | — | OO | Massachusetts | 2021-02-04 | ↗ |
| 20 | Flagship Pioneering, Inc. | 1.85M | 5.20% | — | 1.85M | — | 1.85M | CO | — | 2020-10-29 | ↗ |
| 21 | L.P. | 1.85M | 5.20% | — | 1.85M | — | 1.85M | PN | — | 2020-10-29 | ↗ |
| 22 | Partner LLC | 1.85M | 5.20% | — | 1.85M | — | 1.85M | OO | — | 2020-10-29 | ↗ |
| 23 | Flagship Ventures Opportunities Fund I, L.P. | 1.49M | 4.20% | — | 1.49M | — | 1.49M | PN | — | 2020-10-29 | ↗ |
| 24 | LLC | 1.49M | 4.20% | — | 1.49M | — | 1.49M | OO | — | 2020-10-29 | ↗ |
| 25 | BVF Partners OS Ltd. | 225.8K | 1.00% | — | — | — | 225.8K | CO | Delaware | 2024-05-30 | ↗ |
| 26 | Biotechnology Value Trading Fund OS LP | 225.8K | 1.00% | — | — | — | 225.8K | PN | Delaware | 2024-05-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
104
+11 vs prev Q
New positions
22
Closed positions
11
Increased
62
Reduced
20
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FLAGSHIP PIONEERING INC. | 12.67M +— (+0.0%) | 68.44M +6.5M (+10.4%) | 20.11% -0.016 pp | 21.12% -0.059 pp | USD20.27 -73.4% | 21 qtrs — |
| 2 | FMR LLC | 5.40M -77.7K (-1.4%) | 29.14M +2.4M (+8.9%) | 8.56% -0.130 pp | 0.00% +0.000 pp | USD11.29 -52.2% | 21 qtrs — |
| 3 | BVF INC/IL | 5.30M +— (+0.0%) | 28.63M +2.7M (+10.4%) | 8.41% -0.007 pp | 0.96% -0.087 pp | USD5.84 -7.5% | 7 qtrs — |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3.65M +393.7K (+12.1%) | 19.71M +3.8M (+23.8%) | 5.79% +0.620 pp | 0.25% +0.009 pp | USD6.21 -13.0% | 7 qtrs — |
| 5 | RAYMOND JAMES FINANCIAL INC | 2.51M +43.3K (+1.8%) | 13.53M +1.5M (+12.4%) | 3.98% +0.066 pp | 0.00% +0.000 pp | USD4.66 +15.9% | 5 qtrs — |
| 6 | BLACKROCK, INC. | 2.35M +89.9K (+4.0%) | 12.69M +1.6M (+14.8%) | 3.73% +0.140 pp | 0.00% +0.000 pp | USD8.23 -34.4% | 6 qtrs — |
| 7 | VANGUARD GROUP INC | 1.93M +29.5K (+1.6%) | 10.42M +1.1M (+12.1%) | 3.06% +0.044 pp | 0.00% +0.000 pp | USD11.82 -54.3% | 21 qtrs — |
| 8 | EUCLIDEAN CAPITAL LLC | 1.57M +— (+0.0%) | 8.50M +802.6K (+10.4%) | 2.50% -0.002 pp | 2.30% -0.933 pp | USD17.64 -69.4% | 21 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 795.0K -13.4K (-1.7%) | 4.29M +339.8K (+8.6%) | 1.26% -0.022 pp | 0.00% +0.000 pp | USD11.40 -52.6% | 21 qtrs — |
| 10 | SIREN, L.L.C. | 720.7K +— (+0.0%) | 3.89M +367.6K (+10.4%) | 1.14% -0.001 pp | 0.12% -0.022 pp | USD9.31 -42.0% | 6 qtrs — |
| 11 | STATE STREET CORP | 618.7K -18.5K (-2.9%) | 3.34M +225.1K (+7.2%) | 0.98% -0.030 pp | 0.00% +0.000 pp | USD11.47 -52.9% | 21 qtrs — |
| 12 | AMERIPRISE FINANCIAL INC | 607.7K +607.7K (+100.0%) | 3.28M +3.3M (+100.0%) | 0.96% +0.964 pp | 0.00% +0.001 pp | USD5.40 +0.0% | 3 qtrs — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 297.7K +179.5K (+151.8%) | 1.61M +1.0M (+178.1%) | 0.47% +0.285 pp | 0.00% +0.002 pp | USD5.39 +0.2% | 7 qtrs — |
| 14 | BIRCHVIEW CAPITAL, LP | 281.7K +— (+0.0%) | 1.52M +143.7K (+10.4%) | 0.45% 0.000 pp | 0.89% -0.149 pp | USD17.85 -69.7% | 21 qtrs — |
| 15 | JACOBS LEVY EQUITY MANAGEMENT, INC | 269.2K +85.1K (+46.2%) | 1.45M +553.5K (+61.5%) | 0.43% +0.135 pp | 0.01% +0.002 pp | USD5.62 -3.9% | 12 qtrs — |
| 16 | NORTHERN TRUST CORP | 262.4K -21.9K (-7.7%) | 1.42M +26.9K (+1.9%) | 0.42% -0.035 pp | 0.00% +0.000 pp | USD11.97 -54.9% | 21 qtrs — |
| 17 | MILLENNIUM MANAGEMENT LLC | 208.6K +29.8K (+16.7%) | 1.13M +252.0K (+28.8%) | 0.33% +0.047 pp | 0.00% +0.000 pp | USD5.16 +4.7% | 8 qtrs — |
| 18 | CITADEL ADVISORS LLC | 182.3K +170.2K (+1,415.6%) | 984.3K +925.5K (+1,573.6%) | 0.29% +0.270 pp | 0.00% +0.000 pp | USD5.37 +0.6% | 2 qtrs — |
| 19 | SQUAREPOINT OPS LLC | 141.6K +105.0K (+286.7%) | 764.5K +585.5K (+327.0%) | 0.22% +0.167 pp | 0.00% +0.001 pp | USD5.27 +2.5% | 4 qtrs — |
| 20 | JANE STREET GROUP, LLC | 132.5K +66.1K (+99.6%) | 715.5K +390.9K (+120.4%) | 0.21% +0.105 pp | 0.00% +0.000 pp | USD5.11 +5.7% | 3 qtrs — |
| 21 | DAFNA CAPITAL MANAGEMENT LLC | 126.9K +— (+0.0%) | 685.0K +64.7K (+10.4%) | 0.20% 0.000 pp | 0.16% +0.006 pp | USD4.44 +21.6% | 7 qtrs — |
| 22 | SIO CAPITAL MANAGEMENT, LLC | 122.9K +— (+0.0%) | 663.6K +62.7K (+10.4%) | 0.20% 0.000 pp | 0.10% -0.048 pp | USD6.43 -16.0% | 9 qtrs — |
| 23 | MORGAN STANLEY | 121.7K +58.1K (+91.2%) | 657.3K +346.0K (+111.1%) | 0.19% +0.092 pp | 0.00% +0.000 pp | USD7.69 -29.8% | 21 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 118.7K +46.3K (+63.8%) | 641.0K +286.7K (+80.9%) | 0.19% +0.073 pp | 0.00% +0.000 pp | USD5.93 -8.9% | 18 qtrs — |
| 25 | SCS CAPITAL MANAGEMENT LLC | 107.0K +— (+0.0%) | 577.7K +54.6K (+10.4%) | 0.17% 0.000 pp | 0.01% +0.000 pp | USD3.65 +47.9% | 4 qtrs — |
| 26 | PANAGORA ASSET MANAGEMENT INC | 89.3K +24.0K (+36.7%) | 482.2K +162.7K (+50.9%) | 0.14% +0.038 pp | 0.00% +0.000 pp | USD5.44 -0.7% | 10 qtrs — |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 82.4K -15.8K (-16.1%) | 444.8K -35.4K (-7.4%) | 0.13% -0.025 pp | 0.00% +0.000 pp | USD11.82 -54.3% | 21 qtrs — |
| 28 | WALLEYE CAPITAL LLC | 81.3K +47.0K (+137.1%) | 439.3K +271.5K (+161.8%) | 0.13% +0.075 pp | 0.00% +0.001 pp | USD6.43 -16.0% | 7 qtrs — |
| 29 | BANK OF NEW YORK MELLON CORP | 78.9K -1.6K (-2.0%) | 426.0K +32.5K (+8.3%) | 0.13% -0.003 pp | 0.00% +0.000 pp | USD10.33 -47.7% | 21 qtrs — |
| 30 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 74.6K +— (+0.0%) | 402.8K +38.0K (+10.4%) | 0.12% 0.000 pp | 0.01% +0.001 pp | USD5.19 +4.0% | 7 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 73.9K +43.8K (+145.7%) | 398.8K +251.8K (+171.3%) | 0.12% +0.069 pp | 0.00% +0.000 pp | USD5.70 -5.3% | 21 qtrs — |
| 32 | BARCLAYS PLC | 63.2K +23.3K (+58.3%) | 341.2K -30.4K (-8.2%) | 0.10% +0.037 pp | 0.00% +0.000 pp | USD5.96 -9.4% | 16 qtrs — |
| 33 | POINT72 ASSET MANAGEMENT, L.P. | 62.0K -309.1K (-83.3%) | 334.6K -1.5M (-81.6%) | 0.10% -0.491 pp | 0.00% -0.003 pp | USD5.91 -8.6% | 17 qtrs — |
| 34 | QUBE RESEARCH & TECHNOLOGIES LTD | 53.3K +53.3K (+100.0%) | 287.6K +287.6K (+100.0%) | 0.08% +0.085 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 35 | STATE OF WISCONSIN INVESTMENT BOARD | 53.1K -18.5K (-25.8%) | 287.0K -63.4K (-18.1%) | 0.08% -0.029 pp | 0.00% 0.000 pp | USD5.52 -2.2% | 6 qtrs — |
| 36 | NUVEEN, LLC | 50.1K +— (+0.0%) | 270.7K +25.6K (+10.4%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD3.65 +47.9% | 4 qtrs — |
| 37 | PERSISTENT ASSET PARTNERS LTD | 47.1K +35.7K (+311.7%) | 254.4K +198.4K (+354.7%) | 0.07% +0.057 pp | 0.11% +0.076 pp | USD5.28 +2.3% | 2 qtrs — |
| 38 | RHUMBLINE ADVISERS | 40.1K -3.6K (-8.2%) | 216.6K +2.8K (+1.3%) | 0.06% -0.006 pp | 0.00% +0.000 pp | USD8.67 -37.7% | 19 qtrs — |
| 39 | WELLS FARGO & COMPANY/MN | 38.8K +14.3K (+58.4%) | 209.3K +89.6K (+74.9%) | 0.06% +0.023 pp | 0.00% +0.000 pp | USD5.72 -5.6% | 17 qtrs — |
| 40 | DIADEMA PARTNERS LP | 30.6K -19.4K (-38.7%) | 165.4K -79.1K (-32.4%) | 0.05% -0.031 pp | 0.03% -0.034 pp | USD4.89 +10.4% | 2 qtrs — |
| 41 | MARSHALL WACE, LLP | 28.9K +28.9K (+100.0%) | 156.0K +156.0K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 42 | DEUTSCHE BANK AG\ | 27.4K +1.9K (+7.3%) | 148.1K +23.1K (+18.5%) | 0.04% +0.003 pp | 0.00% +0.000 pp | USD6.97 -22.5% | 21 qtrs — |
| 43 | ALLIANCEBERNSTEIN L.P. | 26.7K +— (+0.0%) | 144.0K +13.6K (+10.4%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD6.22 -13.2% | 11 qtrs — |
| 44 | UBS GROUP AG | 24.5K -10.3K (-29.7%) | 132.3K -38.1K (-22.3%) | 0.04% -0.016 pp | 0.00% +0.000 pp | USD5.23 +3.3% | 13 qtrs — |
| 45 | JUMP FINANCIAL, LLC | 24.1K +24.1K (+100.0%) | 130.3K +130.3K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.002 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 46 | WOODLINE PARTNERS LP | 21.5K -87.1K (-80.2%) | 116.2K -414.8K (-78.1%) | 0.03% -0.138 pp | 0.00% -0.002 pp | USD4.89 +10.4% | 2 qtrs — |
| 47 | METLIFE INVESTMENT MANAGEMENT, LLC | 19.1K -2.1K (-10.1%) | 103.4K -697.0 (-0.7%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD4.70 +14.9% | 3 qtrs — |
| 48 | JPMORGAN CHASE & CO | 17.2K +773.0 (+4.7%) | 93.0K +12.6K (+15.6%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD5.79 -6.7% | 21 qtrs — |
| 49 | TWO SIGMA INVESTMENTS, LP | 16.6K +16.6K (+100.0%) | 89.6K +89.6K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 50 | PRICE T ROWE ASSOCIATES INC /MD/ | 16.4K +— (+0.0%) | 89.0K +8.0K (+9.9%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD4.72 +14.4% | 3 qtrs — |
| 51 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 15.9K +484.0 (+3.1%) | 85.7K +10.5K (+13.9%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD6.31 -14.4% | 7 qtrs — |
| 52 | XTX TOPCO LTD | 15.7K +15.7K (+100.0%) | 84.6K +84.6K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.002 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 53 | INTECH INVESTMENT MANAGEMENT LLC | 14.6K -1.6K (-10.0%) | 78.7K -493.0 (-0.6%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD3.65 +47.9% | 4 qtrs — |
| 54 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 14.3K +11.1K (+350.3%) | 77.1K +61.6K (+397.2%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD5.21 +3.6% | 4 qtrs — |
| 55 | ALGERT GLOBAL LLC | 13.9K +13.9K (+100.0%) | 75.0K +75.0K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.001 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 56 | AQR CAPITAL MANAGEMENT LLC | 13.6K -4.2K (-23.8%) | 73.2K -13.8K (-15.8%) | 0.02% -0.007 pp | 0.00% +0.000 pp | USD3.65 +47.9% | 4 qtrs — |
| 57 | CANADA PENSION PLAN INVESTMENT BOARD | 12.8K +12.8K (+100.0%) | 69.1K +69.1K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 58 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 11.3K +— (+0.0%) | 61.2K +5.8K (+10.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD4.81 +12.3% | 5 qtrs — |
| 59 | FIDUCIARY TRUST CO | 10.9K +— (+0.0%) | 58.7K +5.5K (+10.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD20.27 -73.4% | 21 qtrs — |
| 60 | INVESCO LTD. | 10.8K +10.8K (+100.0%) | 58.2K +58.2K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 61 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 10.5K +10.5K (+100.0%) | 56.6K +56.6K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.001 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 62 | TWO SIGMA ADVISERS, LP | 10.4K +10.4K (+100.0%) | 56.2K +56.2K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 63 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 9.2K -694.0 (-7.0%) | 49.8K +1.3K (+2.7%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD4.72 +14.4% | 5 qtrs — |
| 64 | STRS OHIO | 8.6K +4.7K (+120.5%) | 46.4K +27.4K (+143.5%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD5.17 +4.4% | 2 qtrs — |
| 65 | BNP PARIBAS ARBITRAGE, SNC | 8.3K +1.2K (+16.5%) | 44.7K +9.9K (+28.6%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD4.86 +11.1% | 5 qtrs — |
| 66 | ACADIAN ASSET MANAGEMENT LLC | 7.7K +7.7K (+100.0%) | 41.0K +41.0K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 67 | EVELYN PARTNERS ASSET MANAGEMENT LTD | 7.1K +— (+0.0%) | 38.3K +3.6K (+10.4%) | 0.01% +0.000 pp | 0.01% +0.001 pp | USD4.72 +14.4% | 5 qtrs — |
| 68 | RUSSELL INVESTMENTS GROUP, LTD. | 5.9K +396.0 (+7.1%) | 32.1K +5.0K (+18.3%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD4.95 +9.1% | 6 qtrs — |
| 69 | NISA INVESTMENT ADVISORS, LLC | 5.2K +— (+0.0%) | 28.3K +2.7K (+10.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD6.41 -15.8% | 13 qtrs — |
| 70 | BRUMMER MULTI-STRATEGY AB | 4.7K +4.7K (+100.0%) | 25.4K +25.4K (+100.0%) | 0.01% +0.008 pp | 0.15% +0.154 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 71 | LEGAL & GENERAL GROUP PLC | 3.4K +— (+0.0%) | 18.2K +1.7K (+10.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD9.76 -44.7% | 21 qtrs — |
| 72 | AMERITAS INVESTMENT PARTNERS, INC. | 3.3K +— (+0.0%) | 18.1K +1.7K (+10.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD9.17 -41.1% | 21 qtrs — |
| 73 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.7K +563.0 (+25.8%) | 14.8K +4.2K (+38.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.86 +11.1% | 5 qtrs — |
| 74 | CITIGROUP INC | 2.3K -22.0 (-0.9%) | 12.6K +1.1K (+9.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.09 -33.3% | 21 qtrs — |
| 75 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.1K -431.0 (-17.2%) | 11.2K -1.1K (-8.6%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD4.67 +15.6% | 21 qtrs — |
| 76 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.0K +216.0 (+11.8%) | 11.1K +2.1K (+23.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.46 -59.9% | 21 qtrs — |
| 77 | NEW YORK STATE COMMON RETIREMENT FUND | 1.9K +— (+0.0%) | 10.1K +954.0 (+10.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.46 -52.9% | 21 qtrs — |
| 78 | CWM, LLC | 1.3K -329.0 (-19.6%) | 7.0K -1.0K (-12.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.77 +43.2% | 4 qtrs — |
| 79 | ROYAL BANK OF CANADA | 1.0K -732.0 (-42.2%) | 6.0K -2.0K (-25.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.77 +13.2% | 21 qtrs — |
| 80 | AMALGAMATED BANK | 1.0K +365.0 (+53.6%) | 6.0K +3.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.03 -51.0% | 16 qtrs — |
| 81 | GF FUND MANAGEMENT CO. LTD. | 1.1K -81.0 (-6.8%) | 6.0K +170.0 (+2.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.53 +19.2% | 5 qtrs — |
| 82 | ADVISOR GROUP HOLDINGS, INC. | 1.0K +21.0 (+2.1%) | 5.6K +458.0 (+9.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.71 +14.6% | 3 qtrs — |
| 83 | SUNBELT SECURITIES, INC. | 1.0K -1.0 (-0.1%) | 5.4K +505.0 (+10.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.20 -12.9% | 12 qtrs — |
| 84 | STERLING CAPITAL MANAGEMENT LLC | 847.00 +92.0 (+12.2%) | 4.6K +882.0 (+23.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.04 +7.1% | 6 qtrs — |
| 85 | UBS ASSET MANAGEMENT AMERICAS INC | 374.00 +374.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 86 | GAMMA INVESTING LLC | 364.00 +109.0 (+42.7%) | 2.0K +719.0 (+57.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.04 +7.1% | 5 qtrs — |
| 87 | OPTIVER HOLDING B.V. | 310.00 +— (+0.0%) | 1.7K +158.0 (+10.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.89 +10.4% | 2 qtrs — |
| 88 | NATIONAL BANK OF CANADA /FI/ | 200.00 +200.0 (+100.0%) | 1.1K +1.1K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.40 +0.0% | 1 qtrs NEW |
| 89 | TFC FINANCIAL MANAGEMENT, INC. | 123.00 +— (+0.0%) | 665.00 +63.0 (+10.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.00 +8.0% | 10 qtrs — |
| 90 | SBI SECURITIES CO., LTD. | 100.00 +— (+0.0%) | 540.00 +51.0 (+10.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.65 +47.9% | 5 qtrs — |
| 91 | PNC FINANCIAL SERVICES GROUP, INC. | 84.00 -71.0 (-45.8%) | 454.00 -304.0 (-40.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.45 +21.3% | 7 qtrs — |
| 92 | EVERSOURCE WEALTH ADVISORS, LLC | 75.00 +— (+0.0%) | 405.00 +38.0 (+10.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.64 +48.4% | 4 qtrs — |
| 93 | TRUE WEALTH DESIGN, LLC | 5.00 -6.0 (-54.5%) | 27.00 -27.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.60 +50.0% | 4 qtrs — |
| 94 | PROSHARE ADVISORS LLC | — -15.2K (-100.0%) | — -74.5K (-100.0%) | 0.00% -0.024 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 95 | COLONY GROUP, LLC | — -1.5K (-100.0%) | — -240.3K (-100.0%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 96 | OCCUDO QUANTITATIVE STRATEGIES LP | — -11.9K (-100.0%) | — -58.1K (-100.0%) | 0.00% -0.019 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 97 | TREXQUANT INVESTMENT LP | — -22.0K (-100.0%) | — -107.7K (-100.0%) | 0.00% -0.035 pp | 0.00% -0.001 pp | USD— | 6 qtrs SOLD |
| 98 | ALTA WEALTH ADVISORS LLC | — -10.0K (-100.0%) | — -49.1K (-100.0%) | 0.00% -0.016 pp | 0.00% -0.018 pp | USD— | 9 qtrs SOLD |
| 99 | ALPHABET INC. | — -500.9K (-100.0%) | — -2.4M (-100.0%) | 0.00% -0.795 pp | 0.00% -0.102 pp | USD— | 21 qtrs SOLD |
| 100 | READYSTATE ASSET MANAGEMENT LP | — -161.1K (-100.0%) | — -788.0K (-100.0%) | 0.00% -0.256 pp | 0.00% -0.034 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 46 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.10% | 294.0K | 0.39% |
| 2 | iShares Micro-Cap ETF IWC | 0.05% | 727.9K | 0.60% |
| 3 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.02% | 111.1K | 0.40% |
| 4 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.02% | 17.9K | 0.19% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.02% | 17.5K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.02% | 261.9K | 0.35% |
| 7 | iShares Biotechnology ETF IBB | 0.01% | 1.34M | 0.44% |
| 8 | iShares Russell 2000 Growth ETF IWO | 0.01% | 2.04M | 0.24% |
| 9 | ProShares Ultra Nasdaq Biotechnology BIB | 0.01% | 11.7K | 1.19% |
| 10 | Global X - Russell 2000 ETF RSSL | 0.01% | 101.6K | 0.08% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
10
Sells
0
Shares acquired
7.24M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+7,235,936
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | A | Common Stock | 59,208 | 0.00 | — | 270,912 | I | ↗ |
| 2026-04-09 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | A | Common Stock | 47,497 | 0.00 | — | 211,704 | I | ↗ |
| 2026-02-23 | Maynard Ryan D | Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 5.75 | 2.30M | 400,000 | D | ↗ |
| 2026-02-05 | GOTTSCHALK ADRIAN | Director / Officer | A-Award | A | Stock option (right to buy) | 1,075,000 | 5.23 | 5.62M | 1,075,000 | D | ↗ |
| 2026-01-30 | Rivkin Anna | Officer | A-Award | A | Stock option (right to buy) | 165,000 | 5.71 | 942.2K | 165,000 | D | ↗ |
| 2026-01-30 | LaCascia Michael | Officer | A-Award | A | Stock option (right to buy) | 295,000 | 5.71 | 1.68M | 295,000 | D | ↗ |
| 2026-01-30 | Costa Carlos | Officer | A-Award | A | Stock option (right to buy) | 230,000 | 5.71 | 1.31M | 230,000 | D | ↗ |
| 2026-01-30 | Cardama Alfonso Quintas | Officer | A-Award | A | Stock option (right to buy) | 300,000 | 5.71 | 1.71M | 300,000 | D | ↗ |
| 2026-01-30 | Bellon Steven F. | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 5.71 | 1.71M | 300,000 | D | ↗ |
| 2026-01-13 | Flagship Pioneering, LLC | Director / 10% Owner | A-Award | A | Pre-Funded Warrants to purchase Common Stock | 2,235,468 | 0.00 | 223.55 | 2,235,468 | I | ↗ |
| 2025-11-14 | Humer Kristian | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-17 | SMITH IAN F | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-06-17 | PARSHALL B LYNNE | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-06-17 | Mendelsohn Michael | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-06-17 | Lynch Thomas J. Jr. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-06-17 | GILL SIMBA | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-06-17 | Cole Douglas G. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-06-17 | Biller Scott | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 25,000 | D | ↗ |
| 2025-05-01 | Gallagher Neil | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-01 | Duty Stuart | Director | A-Award | A | Stock Options (Right to buy) | 50,000 | 4.16 | 208.0K | 50,000 | D | ↗ |
| 2025-04-25 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | D | Common Stock | 300,000 | 0.00 | — | 511,704 | I | ↗ |
| 2025-04-09 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | A | Common Stock | 197,906 | 0.00 | — | 511,704 | I | ↗ |
| 2025-01-22 | Rivkin Anna | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 4.37 | 218.5K | 50,000 | D | ↗ |
| 2025-01-22 | LaCascia Michael | Officer | A-Award | A | Stock Option (right to buy) | 126,000 | 4.37 | 550.6K | 126,000 | D | ↗ |
| 2025-01-22 | Humer Kristian | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 4.37 | 524.4K | 120,000 | D | ↗ |
| 2025-01-22 | GOTTSCHALK ADRIAN | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 4.37 | 1.75M | 400,000 | D | ↗ |
| 2025-01-22 | Costa Carlos | Officer | A-Award | A | Stock Option (right to buy) | 115,000 | 4.37 | 502.6K | 115,000 | D | ↗ |
| 2025-01-22 | Cardama Alfonso Quintas | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 4.37 | 546.3K | 125,000 | D | ↗ |
| 2025-01-22 | Bellon Steven F. | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 4.37 | 611.8K | 140,000 | D | ↗ |
| 2024-12-29 | Koppel Adam | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-23 | Costa Carlos | Officer | M-Exempt | A | Common Stock | 857 | 3.72 | 3.2K | 857 | D | ↗ |
| 2024-09-20 | Costa Carlos | Officer | S-Sale | D | Common Stock | 35,756 | 10.04 | 359.0K | 0 | D | ↗ |
| 2024-09-18 | Costa Carlos | Officer | M-Exempt | D | Stock Option (right to buy) | 11,574 | 3.72 | 43.1K | 76,402 | D | ↗ |
| 2024-09-17 | Costa Carlos | Officer | M-Exempt | D | Stock Option (right to buy) | 10,272 | 3.72 | 38.2K | 87,976 | — | ↗ |
| 2024-09-16 | Costa Carlos | Officer | S-Sale | D | Common Stock | 400 | 10.00 | 4.0K | 0 | — | ↗ |
| 2024-09-09 | Bellon Steven F. | Officer | S-Sale | D | Common Stock | 20,000 | 9.50 | 190.0K | 101,957 | — | ↗ |
| 2024-09-03 | Rivkin Anna | Officer | A-Award | A | Stock Options (Right to buy) | 190,000 | 7.85 | 1.49M | 190,000 | — | ↗ |
| 2024-06-26 | SMITH IAN F | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | PARSHALL B LYNNE | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | Mendelsohn Michael | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | Lynch Thomas J. Jr. | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | Koppel Adam | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | GILL SIMBA | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | Cole Douglas G. | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-26 | Biller Scott | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 5.52 | 88.3K | 16,000 | — | ↗ |
| 2024-06-21 | Cavalie Fanny | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-22 | Flagship Pioneering Inc. | 10% Owner | P-Purchase | A | Pre-Funded Warrants to purchase Common Stock | 1,814,914 | 0.00 | 181.49 | 1,814,914 | — | ↗ |
| 2024-05-22 | Flagship Pioneering Fund VII General Partner LLC | 10% Owner | — | I | Pre-Funded Warrants to purchase Common Stock | 1,814,915 | 0.00 | 181.49 | 0 | — | ↗ |
| 2024-04-16 | Humer Kristian | Officer | A-Award | A | Stock Option (Right to buy) | 275,000 | 6.03 | 1.66M | 275,000 | — | ↗ |
| 2024-03-11 | Cavalie Fanny | Officer | S-Sale | D | Common Stock | 11,000 | 6.56 | 72.1K | 75,992 | — | ↗ |
| 2024-01-24 | LaCascia Michael | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 3.06 | 306.0K | 100,000 | — | ↗ |
| 2024-01-24 | GOTTSCHALK ADRIAN | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 3.06 | 918.0K | 300,000 | — | ↗ |
| 2024-01-24 | Costa Carlos | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 3.06 | 275.4K | 90,000 | — | ↗ |
| 2024-01-24 | Cavalie Fanny | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 3.06 | 244.8K | 80,000 | — | ↗ |
| 2024-01-24 | Cardama Alfonso Quintas | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 3.06 | 183.6K | 60,000 | — | ↗ |
| 2024-01-24 | Bellon Steven F. | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 3.06 | 336.6K | 110,000 | — | ↗ |
| 2024-01-16 | Reine Allan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-08 | SMITH IAN F | Director | A-Award | A | Stock Option (right to buy) | 26,977 | 5.63 | 151.9K | 26,977 | — | ↗ |
| 2023-09-11 | Cardama Alfonso Quintas | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-11 | Agresta Samuel | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-17 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | A | Common Stock | 63,000 | 0.00 | — | 511,704 | — | ↗ |
| 2023-08-16 | Agresta Samuel | Officer | M-Exempt | A | Common Stock | 311,297 | 3.72 | 1.16M | 311,297 | — | ↗ |
| 2023-06-21 | SMITH IAN F | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | PARSHALL B LYNNE | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | Mendelsohn Michael | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | Lynch Thomas J. Jr. | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | Koppel Adam | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | GILL SIMBA | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | Cole Douglas G. | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-06-21 | Biller Scott | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 8.70 | 139.2K | 16,000 | — | ↗ |
| 2023-05-26 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | A | Common Stock | 300,000 | 0.00 | — | 448,704 | — | ↗ |
| 2023-02-17 | GOTTSCHALK ADRIAN | Director / Officer | J-Other | A | Common Stock | 184,939 | 0.00 | — | 448,704 | — | ↗ |
| 2023-01-26 | Reine Allan | Director / Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 0.00 | — | 90,000 | — | ↗ |
| 2023-01-26 | LaCascia Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 0.00 | — | 90,000 | — | ↗ |
| 2023-01-26 | GOTTSCHALK ADRIAN | Director / Officer | A-Award | A | Stock Option (right to buy) | 280,000 | 0.00 | — | 280,000 | — | ↗ |
| 2023-01-26 | Costa Carlos | Director / Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2023-01-26 | Cavalie Fanny | Director / Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2023-01-26 | Bellon Steven F. | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-26 | Agresta Samuel | Director / Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-10-27 | Lynch Thomas J. Jr. | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-10-25 | GOTTSCHALK ADRIAN | Director / Officer | J-Other | D | Common Stock | 4,371 | 0.00 | — | 444,333 | — | ↗ |
| 2022-09-13 | GILL SIMBA | Director | G-Gift | D | Common Stock | 47,939 | 0.00 | — | 34,061 | — | ↗ |
| 2022-09-12 | GILL SIMBA | Director | M-Exempt | D | Stock Options (Right to buy) | 82,000 | 0.73 | 59.9K | 107,188 | — | ↗ |
| 2022-08-31 | KADOCH CIGALL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-16 | PARSHALL B LYNNE | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-11 | Bellon Steven F. | Director / Officer | M-Exempt | D | Stock Options (Right to buy) | 1,858 | 0.00 | — | 3,716 | — | ↗ |
| 2022-08-01 | Costa Carlos | Officer | — | — | Stock Options (Right to buy) | 10,135 | 3.72 | 37.7K | 0 | D | ↗ |
| 2022-06-21 | SMITH IAN F | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-21 | Mendelsohn Michael | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-21 | Koppel Adam | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 13.81 | 221.0K | 16,000 | — | ↗ |
| 2022-06-21 | KADOCH CIGALL | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-21 | GILL SIMBA | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-21 | Cole Douglas G. | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-21 | Biller Scott | Director | A-Award | A | Stock Options (Right to buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-05-25 | Bellon Steven F. | Director / Officer | M-Exempt | D | Stock Options (Right to buy) | 675 | 0.00 | — | 0 | — | ↗ |
| 2022-02-14 | Cavalie Fanny | Officer | — | — | Common Stock | 0 | 0.00 | — | 86,992 | D | ↗ |
| 2022-02-10 | GOTTSCHALK ADRIAN | Director / Officer | G-Gift | D | Common Stock | 123,479 | 0.00 | — | 23,000 | — | ↗ |
| 2022-01-26 | Reine Allan | Officer | A-Award | A | Stock Option (right to buy) | 135,000 | 14.87 | 2.01M | 135,000 | — | ↗ |
| 2022-01-26 | LaCascia Michael | Officer | A-Award | A | Stock Option (right to buy) | 135,000 | 14.87 | 2.01M | 135,000 | — | ↗ |
| 2022-01-26 | GOTTSCHALK ADRIAN | Director / Officer | A-Award | A | Stock Option (right to buy) | 440,000 | 14.87 | 6.54M | 440,000 | — | ↗ |
| 2022-01-26 | Bellon Steven F. | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 14.87 | 2.23M | 150,000 | — | ↗ |
| 2022-01-26 | Agresta Samuel | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 14.87 | 1.86M | 125,000 | — | ↗ |
| 2022-01-10 | Bellon Steven F. | Officer | — | D | Stock Options (Right to buy) | 50,000 | 16.63 | 831.5K | 0 | — | ↗ |
| 2021-12-14 | KADOCH CIGALL | Director / 10% Owner | G-Gift | D | Common Stock | 333,333 | 0.00 | — | 295,000 | — | ↗ |
| 2021-12-09 | DECICCO CARL | Officer | M-Exempt | A | Common Stock | 104,310 | 3.72 | 388.0K | 362,707 | — | ↗ |
| 2021-08-20 | GOTTSCHALK ADRIAN | Director / Officer | M-Exempt | D | Stock Options (Right to buy) | 23,000 | 0.54 | 12.4K | 458,925 | — | ↗ |
| 2021-08-09 | Reine Allan | Officer | M-Exempt | A | Stock Options (Right to buy) | 26,892 | 3.72 | 100.0K | 257,512 | — | ↗ |
| 2021-07-13 | Mendelsohn Michael | Director | A-Award | A | Stock Option (right to buy) | 12,530 | 9.40 | 117.8K | 12,530 | — | ↗ |
| 2021-07-13 | Koppel Adam | Director | A-Award | A | Stock Option (right to buy) | 12,530 | 9.40 | 117.8K | 12,530 | — | ↗ |
| 2021-07-13 | KADOCH CIGALL | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 12,530 | 9.40 | 117.8K | 12,530 | — | ↗ |
| 2021-07-13 | GILL SIMBA | Director | A-Award | A | Stock Option (right to buy) | 12,530 | 9.40 | 117.8K | 12,530 | — | ↗ |
| 2021-07-13 | Cole Douglas G. | Director | A-Award | A | Stock Option (right to buy) | 12,530 | 9.40 | 117.8K | 12,530 | — | ↗ |
| 2021-07-13 | Biller Scott | Director | A-Award | A | Stock Option (right to buy) | 12,530 | 9.40 | 117.8K | 12,530 | — | ↗ |
| 2021-06-23 | SMITH IAN F | Director | A-Award | A | Stock Options (Right to buy) | 12,530 | 10.24 | 128.3K | 12,530 | — | ↗ |
| 2021-04-27 | SMITH IAN F | Director | A-Award | A | Stock Options (Right to buy) | 25,060 | 11.50 | 288.2K | 25,060 | — | ↗ |
| 2021-01-28 | Reine Allan | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 16.63 | 2.00M | 120,000 | — | ↗ |
| 2021-01-28 | GOTTSCHALK ADRIAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 16.63 | 4.99M | 300,000 | — | ↗ |
| 2021-01-28 | DECICCO CARL | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 16.63 | 1.66M | 100,000 | — | ↗ |
| 2021-01-28 | Agresta Samuel | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 16.63 | 1.66M | 100,000 | — | ↗ |
| 2020-11-17 | LaCascia Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 162,162 | 17.00 | 2.76M | 162,162 | — | ↗ |
| 2020-11-09 | LaCascia Michael | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-27 | GOTTSCHALK ADRIAN | Director / Officer | C-Conversion | D | Series A-2 Convertible Preferred Stock | 18,018 | 0.00 | — | 0 | — | ↗ |
| 2020-10-27 | Flagship Ventures Fund V General Partner LLC | 10% Owner | C-Conversion | A | Common Stock | 4,504,504 | 0.00 | — | 8,558,558 | — | ↗ |
| 2020-10-27 | DECICCO CARL | Officer | P-Purchase | A | Common Stock | 5,500 | 16.00 | 88.0K | 258,397 | — | ↗ |
| 2020-10-27 | Abu Dhabi Investment Authority | — | C-Conversion | A | Common Stock | 1,081,081 | 35,000,000.00 | 37.84T | 1,081,081 | — | ↗ |
| 2020-10-22 | Reine Allan | Officer | — | D | Stock Option (Right to Buy) | 284,404 | 3.72 | 1.06M | 0 | — | ↗ |
| 2020-10-22 | Mendelsohn Michael | Director | — | D | Stock Option (Right to Buy) | 94,594 | 0.54 | 51.1K | 0 | — | ↗ |
| 2020-10-22 | Koppel Adam | Director | — | D | Stock Option (Right to Buy) | 94,594 | 0.73 | 69.1K | 0 | — | ↗ |
| 2020-10-22 | KADOCH CIGALL | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,957,712 | — | ↗ |
| 2020-10-22 | GOTTSCHALK ADRIAN | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 423,479 | — | ↗ |
| 2020-10-22 | GILL SIMBA | Director | — | D | Stock Option (Right to Buy) | 189,188 | 0.73 | 138.1K | 0 | — | ↗ |
| 2020-10-22 | Flagship Ventures Fund V General Partner LLC | 10% Owner | — | I | Series A-2 Convertible Preferred Stock | 4,504,504 | 0.00 | — | 0 | — | ↗ |
| 2020-10-22 | DECICCO CARL | Officer | — | D | Stock Option (Right to Buy) | 49,982 | 3.72 | 185.9K | 0 | — | ↗ |
| 2020-10-22 | Cole Douglas G. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-22 | Biller Scott | Director | — | D | Stock Option (Right to Buy) | 94,594 | 3.93 | 371.8K | 0 | — | ↗ |
| 2020-10-22 | Bellon Steven F. | Officer | — | D | Common Stock | 0 | 0.00 | — | 128,378 | — | ↗ |
| 2020-10-22 | Baselga Jose | Director | — | D | Common Stock | 0 | 0.00 | — | 94,594 | — | ↗ |
| 2020-10-22 | Agresta Samuel | Officer | — | D | Stock Option (Right to Buy) | 311,297 | 3.72 | 1.16M | 0 | — | ↗ |
| 2020-10-22 | Abu Dhabi Investment Authority | 10% Owner | — | D | Series B Preferred Stock | 1,081,081 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.3K
Shares Outstanding
58.71M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Adrian Gottschalk President and Chief Executive Officer | 638.0K | — | — | 1.33M | 386.0K | 3.0K | 2.36M | 56.50% | ↗ |
| 2 | 2025 | Steven Bellon Chief Science Officer | 505.0K | — | — | 469.3K | 222.2K | 3.0K | 1.20M | 39.12% | ↗ |
| 3 | 2025 | Alfonso Quintás-Cardama Chief Medical Officer | 494.0K | — | — | 419.6K | 217.4K | 3.0K | 1.13M | 37.00% | ↗ |
| 4 | 2024 | Kristian Humer Chief Financial Officer | 336.5K | 87.0K | — | 1.25M | 161.5K | 52.8K | 1.89M | 66.23% | ↗ |
| 5 | 2024 | Adrian Gottschalk President and Chief Executive Officer | 601.5K | — | — | 673.9K | 281.2K | 3.0K | 1.56M | 43.21% | ↗ |
| 6 | 2024 | Anna Rivkin, Ph.D. Chief Business Officer | 143.3K | 135.0K | — | 1.12M | 48.7K | 21.6K | 1.47M | 76.32% | ↗ |
| 7 | 2024 | Steven Bellon Chief Science Officer | 485.0K | — | — | 249.3K | 164.9K | 3.0K | 902.2K | 27.63% | ↗ |
| 8 | 2024 | Alfonso Quintás-Cardama Chief Medical Officer | 471.0K | — | — | 135.3K | 160.1K | 3.0K | 769.5K | 17.59% | ↗ |
| 9 | 2023 | Adrian Gottschalk President and Chief Executive Officer | 579.0K | — | — | 1.72M | 202.7K | 3.0K | 2.50M | 68.66% | ↗ |
| 10 | 2023 | Alfonso Quintás-Cardama Chief Medical Officer | 144.4K | 110.0K | — | 1.54M | 43.4K | 2.3K | 1.84M | 83.73% | ↗ |
| 11 | 2023 | Steven Bellon, Ph.D Chief Scientific Officer | 445.0K | — | — | 614.9K | 124.6K | 3.0K | 1.19M | 51.78% | ↗ |
| 12 | 2022 | Adrian Gottschalk President and Chief Executive Officer | 575.0K | — | — | 4.65M | 215.6K | — | 5.44M | 85.46% | ↗ |
| 13 | 2022 | Steven Bellon, Ph.D Chief Scientific Officer | 435.0K | — | — | 1.58M | 130.5K | — | 2.15M | 73.64% | ↗ |
| 14 | 2022 | Michael LaCascia Chief Legal Officer | 435.0K | — | — | 1.42M | 130.5K | — | 1.99M | 71.56% | ↗ |
| 15 | 2022 | Allan Reine, M.D. Chief Financial Officer | 435.0K | — | — | 1.42M | 130.5K | — | 1.99M | 71.54% | ↗ |
| 16 | 2021 | Adrian Gottschalk President and Chief Executive Officer | 540.0K | — | — | 3.37M | 405.0K | — | 4.32M | 78.10% | ↗ |
| 17 | 2021 | Allan Reine, M.D. Chief Financial Officer | 416.0K | — | — | 1.35M | 249.6K | — | 2.01M | 66.96% | ↗ |
| 18 | 2021 | Samuel Agresta, M.D. Chief Medical Officer | 428.5K | — | — | 1.12M | 257.1K | — | 1.81M | 62.11% | ↗ |
| 19 | 2021 | Carl Decicco, Ph.D. Former Chief Scientific Officer | 428.5K | — | — | 1.12M | 257.1K | — | 1.81M | 62.11% | ↗ |
| 20 | 2021 | Michael LaCascia Chief Legal Officer | 412.0K | — | — | — | 247.2K | — | 659.2K | 0.00% | ↗ |
| 21 | 2020 | Adrian Gottschalk President and Chief Executive Officer | 479.0K | — | — | 1.83M | 311.3K | — | 2.62M | 69.89% | ↗ |
| 22 | 2020 | Michael LaCascia Chief Legal Officer | 59.4K | 60.0K | — | 1.87M | — | — | 1.99M | 94.00% | ↗ |
| 23 | 2020 | Carl Decicco, Ph.D. Chief Scientific Officer | 4.1K | — | — | 542.2K | 214.2K | 50.0K | 1.22M | 44.50% | ↗ |
| 24 | 2020 | Carl Decicco, Ph.D. Former Chief Scientific Officer | 412.0K | — | — | 542.2K | 214.2K | 50.0K | 1.22M | 44.50% | ↗ |
| 25 | 2020 | Samuel Agresta, M.D. Chief Medical Officer | 412.0K | — | — | 542.2K | 99.6K | — | 1.05M | 51.45% | ↗ |
| 26 | 2019 | Carl Decicco, Ph.D. Chief Scientific Officer | 400.0K | — | — | 1.47M | 136.0K | 60.0K | 2.07M | 71.21% | ↗ |
| 27 | 2019 | Adrian Gottschalk President and Chief Executive Officer | 465.0K | — | — | 642.9K | 197.6K | — | 1.31M | 49.25% | ↗ |
| 28 | 2019 | Samuel Agresta, M.D. Chief Medical Officer | 116.7K | 300.0K | — | 785.6K | — | — | 1.20M | 65.34% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adrian H. Gottschalk | President, Chief Executive Officer & Director | 1M | male |
| Steven F. Bellon | Chief Scientific Officer | 730.2K | — |
| Alfonso Quintas Cardama | Chief Medical Officer | 714.4K | — |
| Ryan D. Maynard | Chief Financial Officer | 637.8K | male |
| Michael J. LaCascia | Chief Legal Officer | 565.5K | male |
| Anna Rivkin | Chief Business Officer | 348.7K | — |
| Karin Hellsvik | Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations | — | female |
| Michael Garcia-Webb | VP, Program Executive & Chief of Staff Research | — | — |
| Jeffrey Sacher | Treasurer | — | male |
| Gerald R. Crabtree | Founder & Member of Scientific Advisory Board | — | — |
| Saurabh Sewak | Vice President of Corporate Development | — | male |
| Carlos Costa | Chief People Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FHTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
